SAVED
File name .JPG
File alt. text
Image should be px wide x px tall.
Select Image
home - Colon - Various Colitides - Diversion Colitis Written by Dr Sebastian Zeki

Diversion Colitis

Carbs SCFA’s (butyrate, acetate, propionate) Anaerobic bacterial metabolism Carbohydrates absorbed by ion exchange and diffusion and oxidised by colonocyte Normal Carbs SCFA’s (butyrate, acetate, propionate) Anaerobic bacterial metabolism Diverted colon Histological evidence of diversion colitis = 95%Symptomatic patients =10% Role of Carbohydrate in the Colon They supply 70% of the fuel used by mucosal cells.They modulate fluid and electrolyte transport.They regulate colonic motility.They regulate mucosal blood flow. Histological FeatureDistinction from IBD is difficult.Diffuse cellular infiltrate and prominent lymphoid follicular hyperplasia may suggest diversion colitis. Rectal bleeding, tenesmus, mucus discharge, and abdominal pain Begin within a few months after surgery or after a long delay. Treatments:Reanastomosis.Short chain fatty acid enemas.5 ASA. Diversion colitis Definition— Diversion colitis is an inflammatory process that occurs in segments of the colorectum that are diverted from the fecal stream by surgery. The enema solution consists of sodium acetate (60 mmol), sodium propionate (30 mmol) and sodium n-butyrate (40 mmol) with additional sodium chloride (22 mmol) to yield an osmolality of 280 to 290 mosmol/L which is similar to plasma. The pH is adjusted to 7.0 with sodium hydroxide. -bd for 6 weeks Written by Dr Sebastian Zeki

Related Stories

Identifying key clinical and biochemical predictors of treatment outcomes in inflammatory bowel disease: a real-world evidence study

Tissue-Resident Macrophage-Derived E3 Ligase SMURF2 Restricts Autoimmune Inflammation by Mediating the Degradation of p-TBK1

Electrophysiological and proteomic evidence of protease-mediated pro-nociceptive signaling in inflammatory bowel disease patients

Integrating gut microbiome and host transcriptomics for the personalized management of IBD

Camostat mesylate restores intestinal barrier integrity and attenuated protein loss in experimental protein-losing enteropathy